Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

George I Papakostas, M.D.

Title
Institution
Department
Address
Phone

Research
research activities and funding
The research activities and funding listed below are automatically derived from NIH ExPORTER and other sources, which might result in incorrect or missing items. Faculty can login to make corrections and additions.
Most Recent  |  List All
  1. R01MH081240 (PAPAKOSTAS, GEORGE I) Apr 15, 2008 - Mar 31, 2014
    NIH/NIMH
    1/2-Ziprasidone Augmentation of SSRIs for Treatment-Resistant Depression (TRD)
    Role: Principal Investigator
  2. K23MH069629 (PAPAKOSTAS, GEORGE I) Jan 27, 2004 - Aug 31, 2009
    NIH/NIMH
    S-Adenosyl Methionine(SAMe)Augmentation of SSRIs in MDD
    Role: Principal Investigator

Bibliographic
selected publications
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Kim K, Shin JH, Myung W, Fava M, Mischoulon D, Papakostas GI, Choi KW, Na EJ, Seo SW, Seong JK, Jeon HJ. Deformities of the Globus Pallidus are Associated with Severity of Suicidal Ideation and Impulsivity in Patients with Major Depressive Disorder. Sci Rep. 2019 May 16; 9(1):7462. PMID: 31097766.
    Citations:    
  2. Papakostas GI, Johe K, Hand H, Drouillard A, Russo P, Kay G, Kashambwa R, Hoeppner B, Flynn M, Yeung A, Martinson MA, Fava M. A phase 2, double-blind, placebo-controlled study of NSI-189 phosphate, a neurogenic compound, among outpatients with major depressive disorder. Mol Psychiatry. 2019 Jan 09. PMID: 30626911.
    Citations:    Fields:    
  3. Freeman MP, Papakostas GI, Hoeppner B, Mazzone E, Judge H, Cusin C, Mathew S, Sanacora G, Iosifescu D, DeBattista C, Trivedi MH, Fava M. Sex differences in response to ketamine as a rapidly acting intervention for treatment resistant depression. J Psychiatr Res. 2019 Mar; 110:166-171. PMID: 30641350.
    Citations:    Fields:    
  4. Fava M, Freeman MP, Flynn M, Judge H, Hoeppner BB, Cusin C, Ionescu DF, Mathew SJ, Chang LC, Iosifescu DV, Murrough J, Debattista C, Schatzberg AF, Trivedi MH, Jha MK, Sanacora G, Wilkinson ST, Papakostas GI. Correction: Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD). Mol Psychiatry. 2019 Jan 07. PMID: 30617276.
    Citations:    Fields:    
  5. Salloum NC, Fava M, Freeman MP, Flynn M, Hoeppner B, Hock RS, Cusin C, Iosifescu DV, Trivedi MH, Sanacora G, Mathew SJ, Debattista C, Ionescu DF, Papakostas GI. Efficacy of intravenous ketamine treatment in anxious versus nonanxious unipolar treatment-resistant depression. Depress Anxiety. 2019 03; 36(3):235-243. PMID: 30597688.
    Citations:    Fields:    
  6. Choi KW, Jang EH, Kim AY, Fava M, Mischoulon D, Papakostas GI, Kim DJ, Kim K, Yu HY, Jeon HJ. Heart rate variability for treatment response between patients with major depressive disorder versus panic disorder: A 12-week follow-up study. J Affect Disord. 2019 03 01; 246:157-165. PMID: 30583140.
    Citations:    Fields:    
  7. Kinrys G, Gold AK, Pisano VD, Freeman MP, Papakostas GI, Mischoulon D, Nierenberg AA, Fava M. Tachyphylaxis in major depressive disorder: A review of the current state of research. J Affect Disord. 2019 02 15; 245:488-497. PMID: 30439676.
    Citations:    Fields:    
  8. Fava M, Freeman MP, Flynn M, Judge H, Hoeppner BB, Cusin C, Ionescu DF, Mathew SJ, Chang LC, Iosifescu DV, Murrough J, Debattista C, Schatzberg AF, Trivedi MH, Jha MK, Sanacora G, Wilkinson ST, Papakostas GI. Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD). Mol Psychiatry. 2018 Oct 03. PMID: 30283029.
    Citations:    Fields:    
  9. Laferton JAC, Vijapura S, Baer L, Clain AJ, Cooper A, Papakostas G, Price LH, Carpenter LL, Tyrka AR, Fava M, Mischoulon D. Mechanisms of Perceived Treatment Assignment and Subsequent Expectancy Effects in a Double Blind Placebo Controlled RCT of Major Depression. Front Psychiatry. 2018; 9:424. PMID: 30245644.
    Citations:    
  10. Papakostas GI, Nielsen RZ, Dragheim M, Tonnoir B. Efficacy and tolerability of vortioxetine versus agomelatine, categorized by previous treatment, in patients with major depressive disorder switched after an inadequate response. J Psychiatr Res. 2018 06; 101:72-79. PMID: 29554497.
    Citations:    Fields:    
  11. Iovieno N, Shelton RC, Petrie SR, Cusin C, Fava M, Papakostas GI. Efficacy of Ziprasidone Augmentation of Escitalopram for Cognitive Symptoms of Major Depressive Disorder. J Clin Psychiatry. 2018 Jan/Feb; 79(1). PMID: 28749091.
    Citations:    Fields:    
  12. Kim K, Kim SW, Myung W, Han CE, Fava M, Mischoulon D, Papakostas GI, Seo SW, Cho H, Seong JK, Jeon HJ. Reduced orbitofrontal-thalamic functional connectivity related to suicidal ideation in patients with major depressive disorder. Sci Rep. 2017 Nov 17; 7(1):15772. PMID: 29150619.
    Citations: 2     Fields:    
  13. Fava M, Freeman MP, Flynn M, Hoeppner BB, Shelton R, Iosifescu DV, Murrough JW, Mischoulon D, Cusin C, Rapaport M, Dunlop BW, Trivedi MH, Jha M, Sanacora G, Hermes G, Papakostas GI. Double-blind, proof-of-concept (POC) trial of Low-Field Magnetic Stimulation (LFMS) augmentation of antidepressant therapy in treatment-resistant depression (TRD). Brain Stimul. 2018 Jan - Feb; 11(1):75-84. PMID: 29030111.
    Citations:    Fields:    Translation:Humans
  14. Mischoulon D, Shelton RC, Baer L, Bobo WV, Curren L, Fava M, Papakostas GI. Ziprasidone Augmentation of Escitalopram for Major Depressive Disorder: Cardiac, Endocrine, Metabolic, and Motoric Effects in a Randomized, Double-Blind, Placebo-Controlled Study. J Clin Psychiatry. 2017 04; 78(4):449-455. PMID: 27835715.
    Citations: 1     Fields:    Translation:Humans
  15. Ionescu DF, Papakostas GI. Experimental medication treatment approaches for depression. Transl Psychiatry. 2017 03 21; 7(3):e1068. PMID: 28323287.
    Citations: 4     Fields:    Translation:Humans
  16. Heo JY, Kim K, Fava M, Mischoulon D, Papakostas GI, Kim MJ, Kim DJ, Chang KJ, Oh Y, Yu BH, Jeon HJ. Effects of smartphone use with and without blue light at night in healthy adults: A randomized, double-blind, cross-over, placebo-controlled comparison. J Psychiatr Res. 2017 04; 87:61-70. PMID: 28017916.
    Citations: 3     Fields:    Translation:Humans
  17. Ionescu DF, Shelton RC, Baer L, Meade KH, Swee MB, Fava M, Papakostas GI. Ziprasidone augmentation for anxious depression. Int Clin Psychopharmacol. 2016 11; 31(6):341-6. PMID: 27306192.
    Citations: 1     Fields:    Translation:Humans
  18. Papakostas GI. Identifying Patients Who Need a Change in Depression Treatment and Implementing That Change. J Clin Psychiatry. 2016 08; 77(8):e1009. PMID: 27561146.
    Citations:    Fields:    Translation:Humans
  19. Myung W, Han CE, Fava M, Mischoulon D, Papakostas GI, Heo JY, Kim KW, Kim ST, Kim DJ, Kim DK, Seo SW, Seong JK, Jeon HJ. Reduced frontal-subcortical white matter connectivity in association with suicidal ideation in major depressive disorder. Transl Psychiatry. 2016 06 07; 6(6):e835. PMID: 27271861.
    Citations: 6     Fields:    Translation:Humans
  20. Baek JH, Kim HJ, Fava M, Mischoulon D, Papakostas GI, Nierenberg A, Heo JY, Jeon HJ. Reduced Venous Blood Basophil Count and Anxious Depression in Patients with Major Depressive Disorder. Psychiatry Investig. 2016 May; 13(3):321-6. PMID: 27247599.
    Citations: 2     
  21. Papakostas GI, Martinson MA, Fava M, Iovieno N. Demographic variables, design characteristics, and effect sizes of randomized, placebo-controlled, monotherapy trials of major depressive disorder and bipolar depression. J Clin Psychiatry. 2016 May; 77(5):e619-24. PMID: 27249092.
    Citations: 1     Fields:    Translation:Humans
  22. Zajecka JM, Fava M, Shelton RC, Barrentine LW, Young P, Papakostas GI. Long-term efficacy, safety, and tolerability of L-methylfolate calcium 15 mg as adjunctive therapy with selective serotonin reuptake inhibitors: a 12-month, open-label study following a placebo-controlled acute study. J Clin Psychiatry. 2016 May; 77(5):654-60. PMID: 27035404.
    Citations: 1     Fields:    Translation:Humans
  23. Sarris J, Murphy J, Mischoulon D, Papakostas GI, Fava M, Berk M, Ng CH. Adjunctive Nutraceuticals for Depression: A Systematic Review and Meta-Analyses. Am J Psychiatry. 2016 Jun 01; 173(6):575-87. PMID: 27113121.
    Citations: 21     Fields:    Translation:Humans
  24. Ionescu DF, Papakostas GI. Current Trends in Identifying Rapidly Acting Treatments for Depression. Curr Behav Neurosci Rep. 2016 Jun; 3(2):185-191. PMID: 27574579.
    Citations: 1     
  25. Papakostas GI. Identifying patients with depression who require a change in treatment and implementing that change. J Clin Psychiatry. 2016 Feb; 77 Suppl 1:16-21. PMID: 26829433.
    Citations: 1     Fields:    Translation:Humans
  26. Iovieno N, Nierenberg AA, Parkin SR, Hyung Kim DJ, Walker RS, Fava M, Papakostas GI. Relationship between placebo response rate and clinical trial outcome in bipolar depression. J Psychiatr Res. 2016 Mar; 74:38-44. PMID: 26736040.
    Citations: 2     Fields:    Translation:Humans
  27. Shelton RC, Pencina MJ, Barrentine LW, Ruiz JA, Fava M, Zajecka JM, Papakostas GI. Association of obesity and inflammatory marker levels on treatment outcome: results from a double-blind, randomized study of adjunctive L-methylfolate calcium in patients with MDD who are inadequate responders to SSRIs. J Clin Psychiatry. 2015 Dec; 76(12):1635-41. PMID: 26613389.
    Citations: 7     Fields:    Translation:Humans
  28. Shelton RC, Falola M, Li L, Zajecka J, Fava M, Papakostas GI. The pro-inflammatory profile of depressed patients is (partly) related to obesity. J Psychiatr Res. 2015 Nov; 70:91-7. PMID: 26424427.
    Citations: 9     Fields:    Translation:Humans
  29. Papakostas GI. Antidepressants and their effect on cognition in major depressive disorder. J Clin Psychiatry. 2015 Aug; 76(8):e1046. PMID: 26335095.
    Citations: 5     Fields:    Translation:Humans
  30. Papakostas GI, Shelton RC, Henry ME, Bilello JA. Reply to commentary by Rothschild: "A Blood Test for Depression?". J Clin Psychiatry. 2015 Aug; 76(8):e1038. PMID: 26335092.
    Citations:    Fields:    Translation:Humans
  31. Papakostas GI, Ionescu DF. Towards new mechanisms: an update on therapeutics for treatment-resistant major depressive disorder. Mol Psychiatry. 2015 Oct; 20(10):1142-50. PMID: 26148812.
    Citations: 12     Fields:    Translation:Humans
  32. Yoo I, Woo JM, Lee SH, Fava M, Mischoulon D, Papakostas GI, Kim EJ, Chung S, Ha JH, Jeon HJ. Influence of anxiety symptoms on improvement of neurocognitive functions in patients with major depressive disorder: A 12-week, multicenter, randomized trial of tianeptine versus escitalopram, the CAMPION study. J Affect Disord. 2015 Oct 01; 185:24-30. PMID: 26142691.
    Citations:    Fields:    Translation:Humans
  33. Papakostas GI, Fava M, Baer L, Swee MB, Jaeger A, Bobo WV, Shelton RC. Ziprasidone Augmentation of Escitalopram for Major Depressive Disorder: Efficacy Results From a Randomized, Double-Blind, Placebo-Controlled Study. Am J Psychiatry. 2015 Dec; 172(12):1251-8. PMID: 26085041.
    Citations: 10     Fields:    Translation:Humans
  34. Papakostas GI. Components of cognitive functioning and their measurement. J Clin Psychiatry. 2015 Jun; 76(6):e16. PMID: 26132678.
    Citations:    
  35. Sarris J, Price LH, Carpenter LL, Tyrka AR, Ng CH, Papakostas GI, Jaeger A, Fava M, Mischoulon D. Is S-Adenosyl Methionine (SAMe) for Depression Only Effective in Males? A Re-Analysis of Data from a Randomized Clinical Trial. Pharmacopsychiatry. 2015 Jul; 48(4-5):141-4. PMID: 26011569.
    Citations: 4     Fields:    Translation:Humans
  36. Papakostas GI, Culpepper L. Understanding and managing Cognition in the Depressed Patient. J Clin Psychiatry. 2015 04; 76(4):418-25. PMID: 25919832.
    Citations: 6     Fields:    Translation:Humans
  37. Papakostas GI, Østergaard SD, Iovieno N. The nature of placebo response in clinical studies of major depressive disorder. J Clin Psychiatry. 2015 Apr; 76(4):456-66. PMID: 25700292.
    Citations: 12     Fields:    Translation:Humans
  38. Nierenberg AA, Østergaard SD, Iovieno N, Walker RS, Fava M, Papakostas GI. Predictors of placebo response in bipolar depression. Int Clin Psychopharmacol. 2015 Mar; 30(2):59-66. PMID: 25438027.
    Citations: 4     Fields:    Translation:Humans
  39. Bilello JA, Thurmond LM, Smith KM, Pi B, Rubin R, Wright SM, Taub F, Henry ME, Shelton RC, Papakostas GI. MDDScore: confirmation of a blood test to aid in the diagnosis of major depressive disorder. J Clin Psychiatry. 2015 Feb; 76(2):e199-206. PMID: 25742207.
    Citations: 8     Fields:    Translation:Humans
  40. Heo JY, Jeon HJ, Fava M, Mischoulon D, Baer L, Clain A, Doorley J, Pisoni A, Papakostas GI. Efficacy of ziprasidone monotherapy in patients with anxious depression: a 12-week, randomized, double-blind, placebo-controlled, sequential-parallel comparison trial. J Psychiatr Res. 2015 Mar; 62:56-61. PMID: 25659187.
    Citations: 2     Fields:    Translation:HumansCTClinical Trials
  41. Chen JA, Vijapura S, Papakostas GI, Parkin SR, Kim DJ, Cusin C, Baer L, Clain AJ, Fava M, Mischoulon D. Association between physician beliefs regarding assigned treatment and clinical response: re-analysis of data from the Hypericum Depression Trial Study Group. Asian J Psychiatr. 2015 Feb; 13:23-9. PMID: 25544195.
    Citations:    Fields:    Translation:HumansAnimals
  42. Schatzberg AF, Blier P, Culpepper L, Jain R, Papakostas GI, Thase ME. An overview of vortioxetine. J Clin Psychiatry. 2014 Dec; 75(12):1411-8. PMID: 25551236.
    Citations: 2     Fields:    Translation:HumansAnimals
  43. Papakostas GI, Ionescu DF. Updates and trends in the treatment of major depressive disorder. J Clin Psychiatry. 2014 Dec; 75(12):1419-21. PMID: 25551237.
    Citations: 3     Fields:    Translation:Humans
  44. Jeon HJ, Fava M, Mischoulon D, Baer L, Clain A, Doorley J, DiPierro M, Cardoos A, Papakostas GI. Psychomotor symptoms and treatment outcomes of ziprasidone monotherapy in patients with major depressive disorder: a 12-week, randomized, double-blind, placebo-controlled, sequential parallel comparison trial. Int Clin Psychopharmacol. 2014 Nov; 29(6):332-8. PMID: 24815673.
    Citations: 2     Fields:    Translation:Humans
  45. Mischoulon D, Price LH, Carpenter LL, Tyrka AR, Papakostas GI, Fava M. Dr. Mischoulon and colleagues reply. J Clin Psychiatry. 2014 Nov; 75(11):e1328-9. PMID: 25470103.
    Citations:    Fields:    Translation:Humans
  46. Papakostas GI, Shelton RC, Zajecka JM, Bottiglieri T, Roffman J, Cassiello C, Stahl SM, Fava M. Effect of adjunctive L-methylfolate 15 mg among inadequate responders to SSRIs in depressed patients who were stratified by biomarker levels and genotype: results from a randomized clinical trial. J Clin Psychiatry. 2014 Aug; 75(8):855-63. PMID: 24813065.
    Citations: 7     Fields:    Translation:Humans
  47. Mischoulon D, Price LH, Carpenter LL, Tyrka AR, Papakostas GI, Baer L, Dording CM, Clain AJ, Durham K, Walker R, Ludington E, Fava M. A double-blind, randomized, placebo-controlled clinical trial of S-adenosyl-L-methionine (SAMe) versus escitalopram in major depressive disorder. J Clin Psychiatry. 2014 Apr; 75(4):370-6. PMID: 24500245.
    Citations: 14     Fields:    Translation:Humans
  48. Sarris J, Papakostas GI, Vitolo O, Fava M, Mischoulon D. S-adenosyl methionine (SAMe) versus escitalopram and placebo in major depression RCT: efficacy and effects of histamine and carnitine as moderators of response. J Affect Disord. 2014 Aug; 164:76-81. PMID: 24856557.
    Citations: 6     Fields:    Translation:Humans
  49. Papakostas GI. Cognitive symptoms in patients with major depressive disorder and their implications for clinical practice. J Clin Psychiatry. 2014 Jan; 75(1):8-14. PMID: 24345473.
    Citations: 17     Fields:    Translation:Humans
  50. Bauer M, Demyttenaere K, El-Khalili N, Thase ME, Papakostas GI, Szamosi J, Earley WR, Eriksson H. Pooled analysis of adjunct extended-release quetiapine fumarate in patients with major depressive disorder according to ongoing SSRI or SNRI treatment. Int Clin Psychopharmacol. 2014 Jan; 29(1):16-25. PMID: 24108148.
    Citations: 2     Fields:    Translation:Humans
  51. Cooper JA, Tucker VL, Papakostas GI. Resolution of sleepiness and fatigue: a comparison of bupropion and selective serotonin reuptake inhibitors in subjects with major depressive disorder achieving remission at doses approved in the European Union. J Psychopharmacol. 2014 Feb; 28(2):118-24. PMID: 24352716.
    Citations: 9     Fields:    Translation:Humans
  52. Papakostas GI, Culpepper L, Fayyad RS, Musgnung J, Guico-Pabia CJ. Efficacy of desvenlafaxine 50 mg compared with placebo in patients with moderate or severe major depressive disorder: a pooled analysis of six randomized, double-blind, placebo-controlled studies. Int Clin Psychopharmacol. 2013 Nov; 28(6):312-21. PMID: 23881185.
    Citations:    Fields:    Translation:HumansCTClinical Trials
  53. Nyer M, Farabaugh A, Fehling K, Soskin D, Holt D, Papakostas GI, Pedrelli P, Fava M, Pisoni A, Vitolo O, Mischoulon D. Relationship between sleep disturbance and depression, anxiety, and functioning in college students. Depress Anxiety. 2013 Sep; 30(9):873-80. PMID: 23681944.
    Citations: 10     Fields:    Translation:Humans
  54. Trivedi MH, Bandelow B, Demyttenaere K, Papakostas GI, Papakosts GI, Szamosi J, Earley W, Eriksson H. Evaluation of the effects of extended release quetiapine fumarate monotherapy on sleep disturbance in patients with major depressive disorder: a pooled analysis of four randomized acute studies. Int J Neuropsychopharmacol. 2013 Sep; 16(8):1733-44. PMID: 23673347.
    Citations: 2     Fields:    Translation:Humans
  55. Thase ME, Montgomery S, Papakostas GI, Bauer M, Trivedi MH, Svedsäter H, Locklear JC, Gustafsson U, Datto C, Eriksson H. Quetiapine XR monotherapy in major depressive disorder: a pooled analysis to assess the influence of baseline severity on efficacy. Int Clin Psychopharmacol. 2013 May; 28(3):113-20. PMID: 23485955.
    Citations: 1     Fields:    Translation:HumansCTClinical Trials
  56. Papakostas GI, Shelton RC, Zajecka JM, Etemad B, Rickels K, Clain A, Baer L, Dalton ED, Sacco GR, Schoenfeld D, Pencina M, Meisner A, Bottiglieri T, Nelson E, Mischoulon D, Alpert JE, Barbee JG, Zisook S, Fava M. L-methylfolate as adjunctive therapy for SSRI-resistant major depression: results of two randomized, double-blind, parallel-sequential trials. Am J Psychiatry. 2012 Dec; 169(12):1267-74. PMID: 23212058.
    Citations: 35     Fields:    Translation:Humans
  57. Papakostas GI, Vitolo OV, Ishak WW, Rapaport MH, Zajecka JM, Kinrys G, Mischoulon D, Lipkin SH, Hails KA, Abrams J, Ward SG, Meisner A, Schoenfeld DA, Shelton RC, Winokur A, Okasha MS, Bari MA, Fava M. A 12-week, randomized, double-blind, placebo-controlled, sequential parallel comparison trial of ziprasidone as monotherapy for major depressive disorder. J Clin Psychiatry. 2012 Dec; 73(12):1541-7. PMID: 23290327.
    Citations: 6     Fields:    Translation:Humans
  58. Iovieno N, Papakostas GI. Correlation between different levels of placebo response rate and clinical trial outcome in major depressive disorder: a meta-analysis. J Clin Psychiatry. 2012 Oct; 73(10):1300-6. PMID: 23140647.
    Citations: 21     Fields:    Translation:Humans
  59. Papakostas GI, Cassiello CF, Iovieno N. Folates and S-adenosylmethionine for major depressive disorder. Can J Psychiatry. 2012 Jul; 57(7):406-13. PMID: 22762295.
    Citations: 14     Fields:    Translation:Humans
  60. Mischoulon D, Lamon-Fava S, Selhub J, Katz J, Papakostas GI, Iosifescu DV, Yeung AS, Dording CM, Farabaugh AH, Clain AJ, Baer L, Alpert JE, Nierenberg AA, Fava M. Prevalence of MTHFR C677T and MS A2756G polymorphisms in major depressive disorder, and their impact on response to fluoxetine treatment. CNS Spectr. 2012 Jun; 17(2):76-86. PMID: 22789065.
    Citations: 1     Fields:    Translation:Humans
  61. Mischoulon D, Alpert JE, Arning E, Bottiglieri T, Fava M, Papakostas GI. Bioavailability of S-adenosyl methionine and impact on response in a randomized, double-blind, placebo-controlled trial in major depressive disorder. J Clin Psychiatry. 2012 Jun; 73(6):843-8. PMID: 22687580.
    Citations: 3     Fields:    Translation:Humans
  62. Taneja C, Papakostas GI, Jing Y, Baker RA, Forbes RA, Oster G. Cost-effectiveness of adjunctive therapy with atypical antipsychotics for acute treatment of major depressive disorder. Ann Pharmacother. 2012 May; 46(5):642-9. PMID: 22550279.
    Citations: 4     Fields:    Translation:Humans
  63. Iovieno N, Papakostas GI. Does the presence of an open-label antidepressant treatment period influence study outcome in clinical trials examining augmentation/combination strategies in treatment partial responders/nonresponders with major depressive disorder? J Clin Psychiatry. 2012 May; 73(5):676-83. PMID: 22569112.
    Citations: 4     Fields:    Translation:Humans
  64. Papakostas GI, Shelton RC, Kinrys G, Henry ME, Bakow BR, Lipkin SH, Pi B, Thurmond L, Bilello JA. Assessment of a multi-assay, serum-based biological diagnostic test for major depressive disorder: a pilot and replication study. Mol Psychiatry. 2013 Mar; 18(3):332-9. PMID: 22158016.
    Citations: 35     Fields:    Translation:Humans
  65. Tedeschini E, Levkovitz Y, Iovieno N, Ameral VE, Nelson JC, Papakostas GI. Efficacy of antidepressants for late-life depression: a meta-analysis and meta-regression of placebo-controlled randomized trials. J Clin Psychiatry. 2011 Dec; 72(12):1660-8. PMID: 22244025.
    Citations: 38     Fields:    Translation:Humans
  66. Papakostas GI, Fan H, Tedeschini E. Severe and anxious depression: combining definitions of clinical sub-types to identify patients differentially responsive to selective serotonin reuptake inhibitors. Eur Neuropsychopharmacol. 2012 May; 22(5):347-55. PMID: 22099607.
    Citations: 8     Fields:    Translation:Humans
  67. Chen JA, Papakostas GI, Youn SJ, Baer L, Clain AJ, Fava M, Mischoulon D. Association between patient beliefs regarding assigned treatment and clinical response: reanalysis of data from the Hypericum Depression Trial Study Group. J Clin Psychiatry. 2011 Dec; 72(12):1669-76. PMID: 22053942.
    Citations: 15     Fields:    Translation:HumansAnimals
  68. Pedrelli P, Iovieno N, Vitali M, Tedeschini E, Bentley KH, Papakostas GI. Treatment of major depressive disorder and dysthymic disorder with antidepressants in patients with comorbid opiate use disorders enrolled in methadone maintenance therapy: a meta-analysis. J Clin Psychopharmacol. 2011 Oct; 31(5):582-6. PMID: 21869696.
    Citations: 8     Fields:    Translation:Humans
  69. Mischoulon D, Witte J, Levy M, Papakostas GI, Pet LR, Hsieh WH, Pencina MJ, Ward S, Pollack MH, Fava M. Efficacy of dose increase among nonresponders to low-dose aripiprazole augmentation in patients with inadequate response to antidepressant treatment: a randomized, double-blind, placebo-controlled, efficacy trial. J Clin Psychiatry. 2012 Mar; 73(3):353-7. PMID: 21939613.
    Citations: 2     Fields:    Translation:Humans
  70. Levkovitz Y, Alpert JE, Brintz CE, Mischoulon D, Papakostas GI. Effects of S-adenosylmethionine augmentation of serotonin-reuptake inhibitor antidepressants on cognitive symptoms of major depressive disorder. J Affect Disord. 2012 Feb; 136(3):1174-8. PMID: 21911258.
    Citations: 9     Fields:    Translation:Humans
  71. Papakostas GI. Surrogate markers of treatment outcome in major depressive disorder. Int J Neuropsychopharmacol. 2012 Jul; 15(6):841-54. PMID: 21813045.
    Citations: 4     Fields:    Translation:Humans
  72. Levkovitz Y, Alpert JE, Brintz CE, Mischoulon D, Papakostas GI. Effects of S-adenosylmethionine augmentation of serotonin-reuptake inhibitor antidepressants on cognitive symptoms of major depressive disorder. Eur Psychiatry. 2012 Oct; 27(7):518-21. PMID: 21665441.
    Citations: 1     Fields:    Translation:Humans
  73. Iovieno N, Tedeschini E, Levkovitz Y, Ameral VE, Papakostas GI. Does the frequency of follow-up assessments affect clinical trial outcome? A meta-analysis and meta-regression of placebo-controlled randomized trials. Int J Neuropsychopharmacol. 2012 Apr; 15(3):289-96. PMID: 21557881.
    Citations: 1     Fields:    Translation:Humans
  74. Iovieno N, Tedeschini E, Bentley KH, Evins AE, Papakostas GI. Antidepressants for major depressive disorder and dysthymic disorder in patients with comorbid alcohol use disorders: a meta-analysis of placebo-controlled randomized trials. J Clin Psychiatry. 2011 Aug; 72(8):1144-51. PMID: 21536001.
    Citations: 15     Fields:    Translation:Humans
  75. Levkovitz Y, Tedeschini E, Papakostas GI. Efficacy of antidepressants for dysthymia: a meta-analysis of placebo-controlled randomized trials. J Clin Psychiatry. 2011 Apr; 72(4):509-14. PMID: 21527126.
    Citations: 11     Fields:    Translation:Humans
  76. Dording CM, Mischoulon D, Shyu I, Alpert JE, Papakostas GI. SAMe and sexual functioning. Eur Psychiatry. 2012 Aug; 27(6):451-4. PMID: 21398094.
    Citations: 5     Fields:    Translation:Humans
  77. Iovieno N, Tedeschini E, Ameral VE, Rigatelli M, Papakostas GI. Antidepressants for major depressive disorder in patients with a co-morbid axis-III disorder: a meta-analysis of patient characteristics and placebo response rates in randomized controlled trials. Int Clin Psychopharmacol. 2011 Mar; 26(2):69-74. PMID: 20962663.
    Citations: 6     Fields:    Translation:Humans
  78. Papakostas GI. Reply to Fleisch et al. Letter. Am J Psychiatry. 2010 Dec; 167(12):1533. PMID: 26650135.
    Citations:    Fields:    
  79. Tedeschini E, Fava M, Papakostas GI. Placebo-controlled, antidepressant clinical trials cannot be shortened to less than 4 weeks' duration: a pooled analysis of randomized clinical trials employing a diagnostic odds ratio-based approach. J Clin Psychiatry. 2011 Jan; 72(1):98-113. PMID: 21208576.
    Citations: 4     Fields:    Translation:Humans
  80. Papakostas GI. Switching, combination, and augmentation strategies for major depressive disorder. Ann Clin Psychiatry. 2010 Nov; 22(4 Suppl 3):S9-14. PMID: 21180666.
    Citations:    Fields:    Translation:Humans
  81. Papakostas GI, Larsen K. Testing anxious depression as a predictor and moderator of symptom improvement in major depressive disorder during treatment with escitalopram. Eur Arch Psychiatry Clin Neurosci. 2011 Apr; 261(3):147-56. PMID: 20859636.
    Citations: 6     Fields:    Translation:Humans
  82. Farabaugh A, Sonawalla S, Johnson DP, Witte J, Papakostas GI, Goodness T, Clain A, Baer L, Mischoulon D, Fava M, Harley R. Early improvements in anxiety, depression, and anger/hostility symptoms and response to antidepressant treatment. Ann Clin Psychiatry. 2010 Aug; 22(3):166-71. PMID: 20680189.
    Citations: 3     Fields:    Translation:Humans
  83. Dording CM, Mischoulon D, Goodness TM, Baer L, Clain A, Stewart JW, Matthews JD, McGrath PJ, Nierenberg AA, Fava M, Papakostas GI. Psychoticism and paranoid ideation in patients with nonpsychotic major depressive disorder: prevalence, response to treatment, and impact on short- and long-term treatment outcome. CNS Spectr. 2010 Aug; 15(8):515-21. PMID: 20703198.
    Citations: 1     Fields:    Translation:Humans
  84. Papakostas GI, Mischoulon D, Shyu I, Alpert JE, Fava M. S-adenosyl methionine (SAMe) augmentation of serotonin reuptake inhibitors for antidepressant nonresponders with major depressive disorder: a double-blind, randomized clinical trial. Am J Psychiatry. 2010 Aug; 167(8):942-8. PMID: 20595412.
    Citations: 33     Fields:    Translation:Humans
  85. Farabaugh AH, Bitran S, Witte J, Alpert J, Chuzi S, Clain AJ, Baer L, Fava M, McGrath PJ, Dording C, Mischoulon D, Papakostas GI. Anxious depression and early changes in the HAMD-17 anxiety-somatization factor items and antidepressant treatment outcome. Int Clin Psychopharmacol. 2010 Jul; 25(4):214-7. PMID: 20400905.
    Citations: 8     Fields:    Translation:HumansCTClinical Trials
  86. Fornaro M, Iovieno N, Clementi N, Boscaro M, Paggi F, Balercia G, Fava M, Papakostas GI. Diagnosis of co-morbid axis-I psychiatric disorders among women with newly diagnosed, untreated endocrine disorders. World J Biol Psychiatry. 2010 Dec; 11(8):991-6. PMID: 20569197.
    Citations: 3     Fields:    Translation:Humans
  87. Freeman MP, Mischoulon D, Tedeschini E, Goodness T, Cohen LS, Fava M, Papakostas GI. Complementary and alternative medicine for major depressive disorder: a meta-analysis of patient characteristics, placebo-response rates, and treatment outcomes relative to standard antidepressants. J Clin Psychiatry. 2010 Jun; 71(6):682-8. PMID: 20573327.
    Citations: 14     Fields:    Translation:Humans
  88. Guidi J, Fava GA, Fava M, Papakostas GI. Efficacy of the sequential integration of psychotherapy and pharmacotherapy in major depressive disorder: a preliminary meta-analysis. Psychol Med. 2011 Feb; 41(2):321-31. PMID: 20444307.
    Citations: 15     Fields:    Translation:Humans
  89. Tedeschini E, Fava M, Goodness TM, Papakostas GI. Relationship between probability of receiving placebo and probability of prematurely discontinuing treatment in double-blind, randomized clinical trials for MDD: a meta-analysis. Eur Neuropsychopharmacol. 2010 Aug; 20(8):562-7. PMID: 20219330.
    Citations: 4     Fields:    Translation:Humans
  90. Papakostas GI, Charles D, Fava M. Are typical starting doses of the selective serotonin reuptake inhibitors sub-optimal? A meta-analysis of randomized, double-blind, placebo-controlled, dose-finding studies in major depressive disorder. World J Biol Psychiatry. 2010 Mar; 11(2 Pt 2):300-7. PMID: 20218793.
    Citations: 8     Fields:    Translation:Humans
  91. Yang H, Sinicropi-Yao L, Chuzi S, Youn SJ, Clain A, Baer L, Chen Y, McGrath PJ, Fava M, Papakostas GI. Residual sleep disturbance and risk of relapse during the continuation/maintenance phase treatment of major depressive disorder with the selective serotonin reuptake inhibitor fluoxetine. Ann Gen Psychiatry. 2010 Feb 26; 9:10. PMID: 20187924.
    Citations: 3     
  92. Nutt DJ, Davidson JR, Gelenberg AJ, Higuchi T, Kanba S, Karamustafalioglu O, Papakostas GI, Sakamoto K, Terao T, Zhang M. International consensus statement on major depressive disorder. J Clin Psychiatry. 2010; 71 Suppl E1:e08. PMID: 20371035.
    Citations: 17     Fields:    Translation:HumansPHPublic Health
  93. Papakostas GI. The efficacy, tolerability, and safety of contemporary antidepressants. J Clin Psychiatry. 2010; 71 Suppl E1:e03. PMID: 20371030.
    Citations: 12     Fields:    Translation:Humans
  94. Papakostas GI, Clain A, Ameral VE, Baer L, Brintz C, Smith WT, Londborg PD, Glaudin V, Painter JR, Fava M. Fluoxetine-clonazepam cotherapy for anxious depression: an exploratory, post-hoc analysis of a randomized, double blind study. Int Clin Psychopharmacol. 2010 Jan; 25(1):17-21. PMID: 19898245.
    Citations: 3     Fields:    Translation:Humans
  95. Miller KK, Perlis RH, Papakostas GI, Mischoulon D, Losifescu DV, Brick DJ, Fava M. Low-dose transdermal testosterone augmentation therapy improves depression severity in women. CNS Spectr. 2009 Dec; 14(12):688-94. PMID: 20394176.
    Citations: 9     Fields:    Translation:HumansCTClinical Trials
  96. Papakostas GI. Major depressive disorder: psychosocial impairment and key considerations in functional improvement. Am J Manag Care. 2009 Dec; 15(11 Suppl):S316-21. PMID: 20088627.
    Citations: 6     Fields:    Translation:Humans
  97. Mischoulon D, Papakostas GI, Dording CM, Farabaugh AH, Sonawalla SB, Agoston AM, Smith J, Beaumont EC, Dahan LE, Alpert JE, Nierenberg AA, Fava M. A double-blind, randomized controlled trial of ethyl-eicosapentaenoate for major depressive disorder. J Clin Psychiatry. 2009 Dec; 70(12):1636-44. PMID: 19709502.
    Citations: 24     Fields:    Translation:Humans
  98. Nelson JC, Papakostas GI. Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials. Am J Psychiatry. 2009 Sep; 166(9):980-91. PMID: 19687129.
    Citations: 90     Fields:    Translation:Humans
  99. Papakostas GI, Chuzi SE, Sousa JL, Fava M. 5HT1A-mediated stimulation of cortisol release in major depression: use of non-invasive cortisol measurements to predict clinical response. Eur Arch Psychiatry Clin Neurosci. 2010 Mar; 260(2):175-80. PMID: 19641981.
    Citations: 3     Fields:    Translation:HumansCTClinical Trials
  100. Yang H, Chuzi S, Sinicropi-Yao L, Johnson D, Chen Y, Clain A, Baer L, McGrath PJ, Stewart JW, Fava M, Papakostas GI. Type of residual symptom and risk of relapse during the continuation/maintenance phase treatment of major depressive disorder with the selective serotonin reuptake inhibitor fluoxetine. Eur Arch Psychiatry Clin Neurosci. 2010 Mar; 260(2):145-50. PMID: 19572158.
    Citations: 10     Fields:    Translation:HumansPHPublic HealthCTClinical Trials
  101. Papakostas GI. Initial treatment approaches for patients with major depressive disorder. J Clin Psychiatry. 2009 Jun; 70(6):e18. PMID: 19573474.
    Citations: 1     Fields:    Translation:Humans
  102. Kornstein SG, Li D, Mao Y, Larsson S, Andersen HF, Papakostas GI. Escitalopram versus SNRI antidepressants in the acute treatment of major depressive disorder: integrative analysis of four double-blind, randomized clinical trials. CNS Spectr. 2009 Jun; 14(6):326-33. PMID: 19668123.
    Citations: 10     Fields:    Translation:Humans
  103. Goodwin G, Fleischhacker W, Arango C, Baumann P, Davidson M, de Hert M, Falkai P, Kapur S, Leucht S, Licht R, Naber D, O'Keane V, Papakostas G, Vieta E, Zohar J. Advantages and disadvantages of combination treatment with antipsychotics ECNP Consensus Meeting, March 2008, Nice. Eur Neuropsychopharmacol. 2009 Jul; 19(7):520-32. PMID: 19411165.
    Citations: 23     Fields:    Translation:Humans
  104. Papakostas GI. Diagnostic assessment of major depressive disorder. J Clin Psychiatry. 2009 Apr; 70(4):e09. PMID: 19403094.
    Citations:    Fields:    Translation:Humans
  105. Papakostas GI. Pharmacologic and therapeutic strategies in treatment-resistant depression. Switching antidepressants vs. conventional augmentation strategies. CNS Spectr. 2009 Mar; 14(3 Suppl 4):11-4. PMID: 19407715.
    Citations: 3     Fields:    Translation:Humans
  106. Papakostas GI. Evidence for S-adenosyl-L-methionine (SAM-e) for the treatment of major depressive disorder. J Clin Psychiatry. 2009; 70 Suppl 5:18-22. PMID: 19909689.
    Citations: 13     Fields:    Translation:Humans
  107. Dording CM, Sinicropi-Yao L, Papakostas G, Matthews JD, Nierenberg AA, Fava M, Mischoulon D. The response of psychotic-like symptoms to fluoxetine monotherapy in non-psychotic major depressive disorder. Nord J Psychiatry. 2009; 63(5):420-5. PMID: 19521922.
    Citations:    Fields:    Translation:HumansCTClinical Trials
  108. Papakostas GI, Cooper-Kazaz R, Appelhof BC, Posternak MA, Johnson DP, Klibanski A, Lerer B, Fava M. Simultaneous initiation (coinitiation) of pharmacotherapy with triiodothyronine and a selective serotonin reuptake inhibitor for major depressive disorder: a quantitative synthesis of double-blind studies. Int Clin Psychopharmacol. 2009 Jan; 24(1):19-25. PMID: 19092448.
    Citations: 5     Fields:    Translation:Humans
  109. Papakostas GI. Managing partial response or nonresponse: switching, augmentation, and combination strategies for major depressive disorder. J Clin Psychiatry. 2009; 70 Suppl 6:16-25. PMID: 19922740.
    Citations: 23     Fields:    Translation:Humans
  110. Papakostas GI, Shelton RC. Use of atypical antipsychotics for treatment-resistant major depressive disorder. Curr Psychiatry Rep. 2008 Dec; 10(6):481-6. PMID: 18980731.
    Citations: 5     Fields:    Translation:Humans
  111. Papakostas GI, Fava M. Does the probability of receiving placebo influence clinical trial outcome? A meta-regression of double-blind, randomized clinical trials in MDD. Eur Neuropsychopharmacol. 2009 Jan; 19(1):34-40. PMID: 18823760.
    Citations: 72     Fields:    Translation:Humans
  112. Papakostas GI, McGrath P, Stewart J, Charles D, Chen Y, Mischoulon D, Dording C, Fava M. Psychic and somatic anxiety symptoms as predictors of response to fluoxetine in major depressive disorder. Psychiatry Res. 2008 Oct 30; 161(1):116-20. PMID: 18755514.
    Citations: 9     Fields:    Translation:Humans
  113. Papakostas GI, Stahl SM, Krishen A, Seifert CA, Tucker VL, Goodale EP, Fava M. Efficacy of bupropion and the selective serotonin reuptake inhibitors in the treatment of major depressive disorder with high levels of anxiety (anxious depression): a pooled analysis of 10 studies. J Clin Psychiatry. 2008 Aug; 69(8):1287-92. PMID: 18605812.
    Citations: 19     Fields:    Translation:Humans
  114. Mischoulon D, Best-Popescu C, Laposata M, Merens W, Murakami JL, Wu SL, Papakostas GI, Dording CM, Sonawalla SB, Nierenberg AA, Alpert JE, Fava M. A double-blind dose-finding pilot study of docosahexaenoic acid (DHA) for major depressive disorder. Eur Neuropsychopharmacol. 2008 Sep; 18(9):639-45. PMID: 18539007.
    Citations: 24     Fields:    Translation:HumansCTClinical Trials
  115. Papakostas GI, Homberger CH, Fava M. A meta-analysis of clinical trials comparing mirtazapine with selective serotonin reuptake inhibitors for the treatment of major depressive disorder. J Psychopharmacol. 2008 Nov; 22(8):843-8. PMID: 18308801.
    Citations: 12     Fields:    Translation:Humans
  116. Papakostas GI, Crawford CM, Scalia MJ, Fava M. Timing of clinical improvement and symptom resolution in the treatment of major depressive disorder. A replication of findings with the use of a double-blind, placebo-controlled trial of Hypericum perforatum versus fluoxetine. Neuropsychobiology. 2007; 56(2-3):132-7. PMID: 18259086.
    Citations: 2     Fields:    Translation:HumansAnimalsCTClinical Trials
  117. Shelton RC, Papakostas GI. Augmentation of antidepressants with atypical antipsychotics for treatment-resistant major depressive disorder. Acta Psychiatr Scand. 2008 Apr; 117(4):253-9. PMID: 18190674.
    Citations: 19     Fields:    Translation:Humans
  118. Dording CM, Fisher L, Papakostas G, Farabaugh A, Sonawalla S, Fava M, Mischoulon D. A double-blind, randomized, pilot dose-finding study of maca root (L. meyenii) for the management of SSRI-induced sexual dysfunction. CNS Neurosci Ther. 2008; 14(3):182-91. PMID: 18801111.
    Citations: 8     Fields:    Translation:HumansAnimals
  119. Papakostas GI. Tolerability of modern antidepressants. J Clin Psychiatry. 2008; 69 Suppl E1:8-13. PMID: 18494538.
    Citations: 34     Fields:    Translation:Humans
  120. Papakostas GI, Fava M. Predictors, moderators, and mediators (correlates) of treatment outcome in major depressive disorder. Dialogues Clin Neurosci. 2008; 10(4):439-51. PMID: 19170401.
    Citations: 19     Fields:    Translation:Humans
  121. Papakostas GI. Augmentation strategies in the treatment of major depressive disorder. Examining the evidence on augmentation with atypical antipsychotics. CNS Spectr. 2007 Dec; 12(12 Suppl 22):10-2. PMID: 18396509.
    Citations: 5     Fields:    Translation:Humans
  122. Papakostas GI, Montgomery SA, Thase ME, Katz JR, Krishen A, Tucker VL. Comparing the rapidity of response during treatment of major depressive disorder with bupropion and the SSRIs: a pooled survival analysis of 7 double-blind, randomized clinical trials. J Clin Psychiatry. 2007 Dec; 68(12):1907-12. PMID: 18162022.
    Citations: 3     Fields:    Translation:Humans
  123. Papakostas GI, Fava M, Thase ME. Treatment of SSRI-resistant depression: a meta-analysis comparing within- versus across-class switches. Biol Psychiatry. 2008 Apr 01; 63(7):699-704. PMID: 17919460.
    Citations: 36     Fields:    Translation:Humans
  124. Papakostas GI, Nelson JC, Kasper S, Möller HJ. A meta-analysis of clinical trials comparing reboxetine, a norepinephrine reuptake inhibitor, with selective serotonin reuptake inhibitors for the treatment of major depressive disorder. Eur Neuropsychopharmacol. 2008 Feb; 18(2):122-7. PMID: 17719752.
    Citations: 11     Fields:    Translation:Humans
  125. Simon NM, McNamara K, Chow CW, Maser RS, Papakostas GI, Pollack MH, Nierenberg AA, Fava M, Wong KK. A detailed examination of cytokine abnormalities in Major Depressive Disorder. Eur Neuropsychopharmacol. 2008 Mar; 18(3):230-3. PMID: 17681762.
    Citations: 60     Fields:    Translation:Humans
  126. Papakostas GI, Charles D, Fava M. Are typical starting doses of the selective serotonin reuptake inhibitors sub-optimal? A meta-analysis of randomized, double-blind, placebo-controlled, dose-finding studies in major depressive disorder. World J Biol Psychiatry. 2007 Jul 13; 1-8. PMID: 17853264.
    Citations:    
  127. Papakostas GI, Trivedi MH, Alpert JE, Seifert CA, Krishen A, Goodale EP, Tucker VL. Efficacy of bupropion and the selective serotonin reuptake inhibitors in the treatment of anxiety symptoms in major depressive disorder: a meta-analysis of individual patient data from 10 double-blind, randomized clinical trials. J Psychiatr Res. 2008 Jan; 42(2):134-40. PMID: 17631898.
    Citations: 8     Fields:    Translation:Humans
  128. Papakostas GI, Kornstein SG, Clayton AH, Soares CN, Hallett LA, Krishen A, Tucker VL. Relative antidepressant efficacy of bupropion and the selective serotonin reuptake inhibitors in major depressive disorder: gender-age interactions. Int Clin Psychopharmacol. 2007 Jul; 22(4):226-9. PMID: 17519646.
    Citations: 2     Fields:    Translation:Humans
  129. Papakostas GI, Thase ME, Fava M, Nelson JC, Shelton RC. Are antidepressant drugs that combine serotonergic and noradrenergic mechanisms of action more effective than the selective serotonin reuptake inhibitors in treating major depressive disorder? A meta-analysis of studies of newer agents. Biol Psychiatry. 2007 Dec 01; 62(11):1217-27. PMID: 17588546.
    Citations: 71     Fields:    Translation:Humans
  130. Papakostas GI, Shelton RC, Smith J, Fava M. Augmentation of antidepressants with atypical antipsychotic medications for treatment-resistant major depressive disorder: a meta-analysis. J Clin Psychiatry. 2007 Jun; 68(6):826-31. PMID: 17592905.
    Citations: 43     Fields:    Translation:Humans
  131. Papakostas GI, Fava M. A meta-analysis of clinical trials comparing the serotonin (5HT)-2 receptor antagonists trazodone and nefazodone with selective serotonin reuptake inhibitors for the treatment of major depressive disorder. Eur Psychiatry. 2007 Oct; 22(7):444-7. PMID: 17418537.
    Citations: 2     Fields:    Translation:Humans
  132. Peterson TJ, Feldman G, Harley R, Fresco DM, Graves L, Holmes A, Bogdan R, Papakostas GI, Bohn L, Lury RA, Fava M, Segal ZV. Extreme response style in recurrent and chronically depressed patients: change with antidepressant administration and stability during continuation treatment. J Consult Clin Psychol. 2007 Feb; 75(1):145-53. PMID: 17295573.
    Citations: 8     Fields:    Translation:Humans
  133. Papakostas GI, Hallett LA, Smith J, Tossani E, Mascarini A, Burns AM, Birnbaum RJ, Fava M, Alpert JE. A survey of five antidepressant properties influencing clinician's treatment choices in MDD. Neuropsychiatr Dis Treat. 2007 Feb; 3(1):169-72. PMID: 19300547.
    Citations: 1     
  134. Papakostas GI, Petersen T, Homberger CH, Green CH, Smith J, Alpert JE, Fava M. Hopelessness as a predictor of non-response to fluoxetine in major depressive disorder. Ann Clin Psychiatry. 2007 Jan-Mar; 19(1):5-8. PMID: 17453655.
    Citations: 4     Fields:    Translation:HumansCTClinical Trials
  135. Papakostas GI, Perlis RH, Seifert C, Fava M. Antidepressant dose reduction and the risk of relapse in major depressive disorder. Psychother Psychosom. 2007; 76(5):266-70. PMID: 17700046.
    Citations: 2     Fields:    Translation:Humans
  136. Papakostas GI. Limitations of contemporary antidepressants: tolerability. J Clin Psychiatry. 2007; 68 Suppl 10:11-7. PMID: 17900204.
    Citations: 5     Fields:    Translation:Humans
  137. Papakostas GI, Petersen T, Sklarsky KG, Nierenberg AA, Alpert JE, Fava M. Timing of clinical improvement and symptom resolution in the treatment of major depressive disorder. Psychiatry Res. 2007 Jan 15; 149(1-3):195-200. PMID: 17157390.
    Citations: 7     Fields:    Translation:Humans
  138. Fava M, Graves LM, Benazzi F, Scalia MJ, Iosifescu DV, Alpert JE, Papakostas GI. A cross-sectional study of the prevalence of cognitive and physical symptoms during long-term antidepressant treatment. J Clin Psychiatry. 2006 Nov; 67(11):1754-9. PMID: 17196056.
    Citations: 40     Fields:    Translation:HumansPHPublic Health
  139. Papakostas GI. Major depressive disorder: similar remission rates with bupropion, sertraline, or venlafaxine following treatment switch from citalopram. Evid Based Ment Health. 2006 Nov; 9(4):100. PMID: 17065297.
    Citations: 1     Fields:    
  140. Papakostas GI, Fava M. A metaanalysis of clinical trials comparing moclobemide with selective serotonin reuptake inhibitors for the treatment of major depressive disorder. Can J Psychiatry. 2006 Oct; 51(12):783-90. PMID: 17168253.
    Citations: 6     Fields:    Translation:Humans
  141. Papakostas GI, Nutt DJ, Hallett LA, Tucker VL, Krishen A, Fava M. Resolution of sleepiness and fatigue in major depressive disorder: A comparison of bupropion and the selective serotonin reuptake inhibitors. Biol Psychiatry. 2006 Dec 15; 60(12):1350-5. PMID: 16934768.
    Citations: 30     Fields:    Translation:Humans
  142. Denninger JW, Papakostas GI, Mahal Y, Merens W, Alpert JE, Nierenberg AA, Yeung A, Fava M. Somatic symptoms in outpatients with major depressive disorder treated with fluoxetine. Psychosomatics. 2006 Jul-Aug; 47(4):348-52. PMID: 16844895.
    Citations: 5     Fields:    Translation:Humans
  143. Papakostas GI, Fava M. A meta-analysis of clinical trials comparing milnacipran, a serotonin--norepinephrine reuptake inhibitor, with a selective serotonin reuptake inhibitor for the treatment of major depressive disorder. Eur Neuropsychopharmacol. 2007 Jan; 17(1):32-6. PMID: 16762534.
    Citations: 7     Fields:    Translation:HumansCTClinical Trials
  144. Papakostas GI, Miller KK, Petersen T, Sklarsky KG, Hilliker SE, Klibanski A, Fava M. Serum prolactin levels among outpatients with major depressive disorder during the acute phase of treatment with fluoxetine. J Clin Psychiatry. 2006 Jun; 67(6):952-7. PMID: 16848655.
    Citations: 9     Fields:    Translation:HumansCTClinical Trials
  145. Farabaugh AH, Sonawalla SB, Fava M, Pedrelli P, Papakostas GI, Schwartz F, Mischoulon D. Differences in cognitive factors between "true drug" versus "placebo pattern" response to fluoxetine as defined by pattern analysis. Hum Psychopharmacol. 2006 Jun; 21(4):221-5. PMID: 16783809.
    Citations: 1     Fields:    Translation:HumansCTClinical Trials
  146. Papakostas GI, Petersen TJ, Perlis RH, Judy AE, Burns AM, Alpert JE, Birnbaum RJ, Fava M. A survey of antidepressant prescribing practices in major depression with comorbid attention-deficit hyperactivity disorder. J Clin Psychopharmacol. 2006 Apr; 26(2):216-8. PMID: 16633159.
    Citations:    Fields:    Translation:Humans
  147. Papakostas GI, Perlis RH, Scalia MJ, Petersen TJ, Fava M. A meta-analysis of early sustained response rates between antidepressants and placebo for the treatment of major depressive disorder. J Clin Psychopharmacol. 2006 Feb; 26(1):56-60. PMID: 16415707.
    Citations: 18     Fields:    Translation:Humans
  148. Iosifescu DV, Renshaw PF, Lyoo IK, Lee HK, Perlis RH, Papakostas GI, Nierenberg AA, Fava M. Brain white-matter hyperintensities and treatment outcome in major depressive disorder. Br J Psychiatry. 2006 Feb; 188:180-5. PMID: 16449707.
    Citations: 15     Fields:    Translation:Humans
  149. Papakostas GI. Dopaminergic-based pharmacotherapies for depression. Eur Neuropsychopharmacol. 2006 Aug; 16(6):391-402. PMID: 16413172.
    Citations: 22     Fields:    Translation:HumansAnimals
  150. Harley R, Petersen T, Scalia M, Papakostas GI, Farabaugh A, Fava M. Problem-solving ability and comorbid personality disorders in depressed outpatients. Depress Anxiety. 2006; 23(8):496-501. PMID: 16845662.
    Citations:    Fields:    Translation:HumansCTClinical Trials
  151. Souery D, Papakostas GI, Trivedi MH. Treatment-resistant depression. J Clin Psychiatry. 2006; 67 Suppl 6:16-22. PMID: 16848672.
    Citations: 39     Fields:    Translation:Humans
  152. Petersen T, Iosifescu DV, Papakostas GI, Shear DL, Fava M. Clinical characteristics of depressed patients with comorbid diabetes mellitus. Int Clin Psychopharmacol. 2006 Jan; 21(1):43-7. PMID: 16317316.
    Citations:    Fields:    Translation:Humans
  153. Nutt DJ, Baldwin DS, Clayton AH, Elgie R, Lecrubier Y, Montejo AL, Papakostas GI, Souery D, Trivedi MH, Tylee A. Consensus statement and research needs: the role of dopamine and norepinephrine in depression and antidepressant treatment. J Clin Psychiatry. 2006; 67 Suppl 6:46-9. PMID: 16848678.
    Citations: 6     Fields:    Translation:Humans
  154. Baldwin DS, Papakostas GI. Symptoms of fatigue and sleepiness in major depressive disorder. J Clin Psychiatry. 2006; 67 Suppl 6:9-15. PMID: 16848671.
    Citations: 16     Fields:    Translation:Humans
  155. Papakostas GI, Worthington JJ, Iosifescu DV, Kinrys G, Burns AM, Fisher LB, Homberger CH, Mischoulon D, Fava M. The combination of duloxetine and bupropion for treatment-resistant major depressive disorder. Depress Anxiety. 2006; 23(3):178-81. PMID: 16528701.
    Citations: 9     Fields:    Translation:Humans
  156. Iosifescu DV, Papakostas GI, Lyoo IK, Lee HK, Renshaw PF, Alpert JE, Nierenberg A, Fava M. Brain MRI white matter hyperintensities and one-carbon cycle metabolism in non-geriatric outpatients with major depressive disorder (Part I). Psychiatry Res. 2005 Dec 30; 140(3):291-9. PMID: 16298109.
    Citations: 3     Fields:    Translation:Humans
  157. Fraguas R, Papakostas GI, Mischoulon D, Bottiglieri T, Alpert J, Fava M. Anger attacks in major depressive disorder and serum levels of homocysteine. Biol Psychiatry. 2006 Aug 01; 60(3):270-4. PMID: 16325154.
    Citations: 5     Fields:    Translation:Humans
  158. Papakostas GI, Iosifescu DV, Renshaw PF, Lyoo IK, Lee HK, Alpert JE, Nierenberg AA, Fava M. Brain MRI white matter hyperintensities and one-carbon cycle metabolism in non-geriatric outpatients with major depressive disorder (Part II). Psychiatry Res. 2005 Dec 30; 140(3):301-7. PMID: 16297603.
    Citations: 5     Fields:    Translation:Humans
  159. Papakostas GI, Petersen TJ, Kinrys G, Burns AM, Worthington JJ, Alpert JE, Fava M, Nierenberg AA. Aripiprazole augmentation of selective serotonin reuptake inhibitors for treatment-resistant major depressive disorder. J Clin Psychiatry. 2005 Oct; 66(10):1326-30. PMID: 16259548.
    Citations: 22     Fields:    Translation:Humans
  160. Iosifescu DV, Clementi-Craven N, Fraguas R, Papakostas GI, Petersen T, Alpert JE, Nierenberg AA, Fava M. Cardiovascular risk factors may moderate pharmacological treatment effects in major depressive disorder. Psychosom Med. 2005 Sep-Oct; 67(5):703-6. PMID: 16204427.
    Citations: 12     Fields:    Translation:Humans
  161. Petersen T, Papakostas GI, Posternak MA, Kant A, Guyker WM, Iosifescu DV, Yeung AS, Nierenberg AA, Fava M. Empirical testing of two models for staging antidepressant treatment resistance. J Clin Psychopharmacol. 2005 Aug; 25(4):336-41. PMID: 16012276.
    Citations: 20     Fields:    Translation:Humans
  162. Iosifescu DV, Nierenberg AA, Mischoulon D, Perlis RH, Papakostas GI, Ryan JL, Alpert JE, Fava M. An open study of triiodothyronine augmentation of selective serotonin reuptake inhibitors in treatment-resistant major depressive disorder. J Clin Psychiatry. 2005 Aug; 66(8):1038-42. PMID: 16086620.
    Citations: 7     Fields:    Translation:HumansCTClinical Trials
  163. Papakostas GI, Petersen TJ, Green C, Iosifescu DV, Yeung AS, Nierenberg AA, Fava M, Posternak MA. A description of next-step switching versus augmentation practices for outpatients with treatment-resistant major depressive disorder enrolled in an academic specialty clinic. Ann Clin Psychiatry. 2005 Jul-Sep; 17(3):161-5. PMID: 16433058.
    Citations: 4     Fields:    Translation:Humans
  164. Papakostas GI, Petersen TJ, Burns AM, Fava M. Adjunctive atomoxetine for residual fatigue in major depressive disorder. J Psychiatr Res. 2006 Jun; 40(4):370-3. PMID: 15978621.
    Citations: 5     Fields:    Translation:Humans
  165. Papakostas GI, Petersen T, Lebowitz BD, Mischoulon D, Ryan JL, Nierenberg AA, Bottiglieri T, Alpert JE, Rosenbaum JF, Fava M. The relationship between serum folate, vitamin B12, and homocysteine levels in major depressive disorder and the timing of improvement with fluoxetine. Int J Neuropsychopharmacol. 2005 Dec; 8(4):523-8. PMID: 15877935.
    Citations: 11     Fields:    Translation:HumansCTClinical Trials
  166. Papakostas GI. Augmentation of standard antidepressants with atypical antipsychotic agents for treatment-resistant major depressive disorder. Essent Psychopharmacol. 2005; 6(4):209-20. PMID: 16041917.
    Citations: 5     Fields:    Translation:Humans
  167. Alpert JE, Papakostas G, Mischoulon D, Worthington JJ, Petersen T, Mahal Y, Burns A, Bottiglieri T, Nierenberg AA, Fava M. S-adenosyl-L-methionine (SAMe) as an adjunct for resistant major depressive disorder: an open trial following partial or nonresponse to selective serotonin reuptake inhibitors or venlafaxine. J Clin Psychopharmacol. 2004 Dec; 24(6):661-4. PMID: 15538131.
    Citations: 21     Fields:    Translation:HumansCTClinical Trials
  168. Misra M, Papakostas GI, Klibanski A. Effects of psychiatric disorders and psychotropic medications on prolactin and bone metabolism. J Clin Psychiatry. 2004 Dec; 65(12):1607-18; quiz 1590, 1760-1. PMID: 15641865.
    Citations: 23     Fields:    Translation:Humans
  169. Papakostas GI, Petersen T, Denninger JW, Tossani E, Pava JA, Alpert JE, Nierenberg AA, Fava M. Psychosocial functioning during the treatment of major depressive disorder with fluoxetine. J Clin Psychopharmacol. 2004 Oct; 24(5):507-11. PMID: 15349006.
    Citations: 16     Fields:    Translation:HumansCTClinical Trials
  170. Papakostas GI, Petersen T, Iosifescu DV, Burns AM, Nierenberg AA, Alpert JE, Rosenbaum JF, Fava M. Obesity among outpatients with major depressive disorder. Int J Neuropsychopharmacol. 2005 Mar; 8(1):59-63. PMID: 15361263.
    Citations: 13     Fields:    Translation:HumansCTClinical Trials
  171. Iosifescu DV, Nierenberg AA, Alpert JE, Papakostas GI, Perlis RH, Sonawalla S, Fava M. Comorbid medical illness and relapse of major depressive disorder in the continuation phase of treatment. Psychosomatics. 2004 Sep-Oct; 45(5):419-25. PMID: 15345787.
    Citations: 9     Fields:    Translation:Humans
  172. Papakostas GI, Petersen T, Mischoulon D, Green CH, Nierenberg AA, Bottiglieri T, Rosenbaum JF, Alpert JE, Fava M. Serum folate, vitamin B12, and homocysteine in major depressive disorder, Part 2: predictors of relapse during the continuation phase of pharmacotherapy. J Clin Psychiatry. 2004 Aug; 65(8):1096-8. PMID: 15323595.
    Citations: 12     Fields:    Translation:HumansCTClinical Trials
  173. Papakostas GI, Iosifescu DV, Petersen T, Hamill SK, Alpert JE, Nierenberg AA, Rosenbaum JF, Fava M. Serum cholesterol in the continuation phase of pharmacotherapy with fluoxetine in remitted major depressive disorder. J Clin Psychopharmacol. 2004 Aug; 24(4):467-9. PMID: 15232350.
    Citations: 3     Fields:    Translation:HumansCTClinical Trials
  174. Papakostas GI, Petersen T, Mischoulon D, Ryan JL, Nierenberg AA, Bottiglieri T, Rosenbaum JF, Alpert JE, Fava M. Serum folate, vitamin B12, and homocysteine in major depressive disorder, Part 1: predictors of clinical response in fluoxetine-resistant depression. J Clin Psychiatry. 2004 Aug; 65(8):1090-5. PMID: 15323594.
    Citations: 22     Fields:    Translation:HumansCTClinical Trials
  175. Petersen T, Papakostas GI, Mahal Y, Guyker WM, Beaumont EC, Alpert JE, Fava M, Nierenberg AA. Psychosocial functioning in patients with treatment resistant depression. Eur Psychiatry. 2004 Jun; 19(4):196-201. PMID: 15196600.
    Citations: 4     Fields:    Translation:Humans
  176. Papakostas GI, Petersen T, Hughes ME, Nierenberg AA, Alpert JE, Fava M. Anxiety and somatic symptoms as predictors of treatment-related adverse events in major depressive disorder. Psychiatry Res. 2004 May 30; 126(3):287-90. PMID: 15157754.
    Citations: 8     Fields:    Translation:Humans
  177. Petersen T, Harley R, Papakostas GI, Montoya HD, Fava M, Alpert JE. Continuation cognitive-behavioural therapy maintains attributional style improvement in depressed patients responding acutely to fluoxetine. Psychol Med. 2004 Apr; 34(3):555-61. PMID: 15259840.
    Citations: 5     Fields:    Translation:HumansPHPublic HealthCTClinical Trials
  178. Papakostas GI, Petersen TJ, Iosifescu DV, Summergrad P, Sklarsky KG, Alpert JE, Nierenberg AA, Fava M. Somatic symptoms as predictors of time to onset of response to fluoxetine in major depressive disorder. J Clin Psychiatry. 2004 Apr; 65(4):543-6. PMID: 15119918.
    Citations: 7     Fields:    Translation:Humans
  179. Papakostas GI, Ongür D, Iosifescu DV, Mischoulon D, Fava M. Cholesterol in mood and anxiety disorders: review of the literature and new hypotheses. Eur Neuropsychopharmacol. 2004 Mar; 14(2):135-42. PMID: 15013029.
    Citations: 19     Fields:    Translation:HumansAnimals
  180. Papakostas GI, Petersen TJ, Nierenberg AA, Murakami JL, Alpert JE, Rosenbaum JF, Fava M. Ziprasidone augmentation of selective serotonin reuptake inhibitors (SSRIs) for SSRI-resistant major depressive disorder. J Clin Psychiatry. 2004 Feb; 65(2):217-21. PMID: 15003076.
    Citations: 30     Fields:    Translation:HumansCTClinical Trials
  181. Papakostas GI, Petersen T, Mahal Y, Mischoulon D, Nierenberg AA, Fava M. Quality of life assessments in major depressive disorder: a review of the literature. Gen Hosp Psychiatry. 2004 Jan-Feb; 26(1):13-7. PMID: 14757297.
    Citations: 53     Fields:    Translation:Humans
  182. Papakostas GI, Alpert JE, Fava M. S-adenosyl-methionine in depression: a comprehensive review of the literature. Curr Psychiatry Rep. 2003 Dec; 5(6):460-6. PMID: 14609501.
    Citations: 17     Fields:    Translation:Humans
  183. Papakostas GI, Petersen TJ, Farabaugh AH, Murakami JL, Pava JA, Alpert JE, Fava M, Nierenberg AA. Psychiatric comorbidity as a predictor of clinical response to nortriptyline in treatment-resistant major depressive disorder. J Clin Psychiatry. 2003 Nov; 64(11):1357-61. PMID: 14658951.
    Citations: 3     Fields:    Translation:HumansCTClinical Trials
  184. Papakostas GI, Petersen T, Worthington JJ, Roffi PA, Alpert JE, Fava M, Nierenberg AA. A pilot, open study of sertraline in outpatients with treatment-resistant depression (TRD) or with a history of TRD who responded but later relapsed. Int Clin Psychopharmacol. 2003 Sep; 18(5):293-6. PMID: 12920390.
    Citations:    Fields:    Translation:HumansCTClinical Trials
  185. Papakostas GI, Petersen T, Denninger JW, Montoya HD, Nierenberg AA, Alpert JE, Fava M. Treatment-related adverse events and outcome in a clinical trial of fluoxetine for major depressive disorder. Ann Clin Psychiatry. 2003 Sep-Dec; 15(3-4):187-92. PMID: 14971864.
    Citations:    Fields:    Translation:HumansCTClinical Trials
  186. Papakostas GI, Petersen T, Pava J, Masson E, Worthington JJ, Alpert JE, Fava M, Nierenberg AA. Hopelessness and suicidal ideation in outpatients with treatment-resistant depression: prevalence and impact on treatment outcome. J Nerv Ment Dis. 2003 Jul; 191(7):444-9. PMID: 12891091.
    Citations: 9     Fields:    Translation:Humans
  187. Papakostas YG, Eftychiadis A, Papakostas GI, Christodoulou GN. A historical inquiry into the appropriateness of the term "panic disorder". Hist Psychiatry. 2003 Jun; 14(54 Pt 2):195-204. PMID: 14518489.
    Citations:    Fields:    
  188. Papakostas GI, Petersen T, Mischoulon D, Hughes ME, Alpert JE, Nierenberg AA, Rosenbaum JF, Fava M. Serum cholesterol and serotonergic function in major depressive disorder. Psychiatry Res. 2003 May 30; 118(2):137-45. PMID: 12798978.
    Citations: 4     Fields:    Translation:Humans
  189. Papakostas GI, Petersen T, Iosifescu DV, Roffi PA, Alpert JE, Rosenbaum JF, Fava M, Nierenberg AA. Axis III disorders in treatment-resistant major depressive disorder. Psychiatry Res. 2003 May 30; 118(2):183-8. PMID: 12798983.
    Citations: 8     Fields:    Translation:HumansCTClinical Trials
  190. Papakostas GI, Petersen T, Denninger J, Sonawalla SB, Mahal Y, Alpert JE, Nierenberg AA, Fava M. Somatic symptoms in treatment-resistant depression. Psychiatry Res. 2003 May 01; 118(1):39-45. PMID: 12759160.
    Citations: 11     Fields:    Translation:HumansCTClinical Trials
  191. Fava M, Papakostas GI, Petersen T, Mahal Y, Quitkin F, Stewart J, McGrath P. Switching to bupropion in fluoxetine-resistant major depressive disorder. Ann Clin Psychiatry. 2003 Mar; 15(1):17-22. PMID: 12839429.
    Citations: 6     Fields:    Translation:HumansCTClinical Trials
  192. Alpert JE, Petersen T, Roffi PA, Papakostas GI, Freed R, Smith MM, Spector AR, Nierenberg AA, Rosenbaum JF, Fava M. Behavioral and emotional disturbances in the offspring of depressed parents with anger attacks. Psychother Psychosom. 2003 Mar-Apr; 72(2):102-6. PMID: 12601228.
    Citations: 4     Fields:    Translation:Humans
  193. Nierenberg AA, Papakostas GI, Petersen T, Montoya HD, Worthington JJ, Tedlow J, Alpert JE, Fava M. Lithium augmentation of nortriptyline for subjects resistant to multiple antidepressants. J Clin Psychopharmacol. 2003 Feb; 23(1):92-5. PMID: 12544380.
    Citations: 14     Fields:    Translation:HumansCTClinical Trials
  194. Petersen TJ, Alpert JE, Papakostas GI, Bernstein EM, Freed R, Smith MM, Fava M. Early-onset depression and the emotional and behavioral characteristics of offspring. Depress Anxiety. 2003; 18(2):104-8. PMID: 12964178.
    Citations:    Fields:    Translation:Humans
  195. Papakostas GI, Petersen T, Sonawalla SB, Merens W, Iosifescu DV, Alpert JE, Fava M, Nierenberg AA. Serum cholesterol in treatment-resistant depression. Neuropsychobiology. 2003; 47(3):146-51. PMID: 12759558.
    Citations: 10     Fields:    Translation:HumansCTClinical Trials
  196. Papakostas GI, Petersen T, Mischoulon D, Hughes ME, Spector AR, Alpert JE, Fava M, Nierenberg AA. Functioning and interpersonal relationships as predictors of response in treatment-resistant depression. Compr Psychiatry. 2003 Jan-Feb; 44(1):44-50. PMID: 12524635.
    Citations: 4     Fields:    Translation:Humans
  197. Nierenberg AA, Papakostas GI, Petersen T, Kelly KE, Iacoviello BM, Worthington JJ, Tedlow J, Alpert JE, Fava M. Nortriptyline for treatment-resistant depression. J Clin Psychiatry. 2003 Jan; 64(1):35-9. PMID: 12590621.
    Citations: 8     Fields:    Translation:HumansCTClinical Trials
  198. Petersen T, Hughes M, Papakostas GI, Kant A, Fava M, Rosenbaum JF, Nierenberg AA. Treatment-resistant depression and Axis II comorbidity. Psychother Psychosom. 2002 Sep-Oct; 71(5):269-74. PMID: 12207107.
    Citations: 2     Fields:    Translation:HumansCTClinical Trials
  199. Sonawalla SB, Papakostas GI, Petersen TJ, Yeung AS, Smith MM, Sickinger AH, Gordon J, Israel JA, Tedlow JR, Lamon-Fava S, Fava M. Elevated cholesterol levels associated with nonresponse to fluoxetine treatment in major depressive disorder. Psychosomatics. 2002 Jul-Aug; 43(4):310-6. PMID: 12189257.
    Citations: 7     Fields:    Translation:Humans
  200. Petersen T, Papakostas GI, Bottonari K, Iacoviello B, Alpert JE, Fava M, Nierenberg AA. NEO-FFI factor scores as predictors of clinical response to fluoxetine in depressed outpatients. Psychiatry Res. 2002 Jan 31; 109(1):9-16. PMID: 11850046.
    Citations: 7     Fields:    Translation:HumansCTClinical Trials
  201. Kornbluh R, Papakostas GI, Petersen T, Neault NB, Nierenberg AA, Rosenbaum JF, Fava M. A survey of prescribing preferences in the treatment of refractory depression: recent trends. Psychopharmacol Bull. 2001; 35(3):150-6. PMID: 12397884.
    Citations: 2     Fields:    Translation:Humans
  202. Goutner V, Furness RW, Papakostas G. Mercury in feathers of Squacco Heron (Ardeola ralloides) chicks in relation to age, hatching order, growth, and sampling dates. Environ Pollut. 2001; 111(1):107-15. PMID: 11202703.
    Citations: 2     Fields:    Translation:AnimalsPHPublic Health
  203. Dean AC, Solomon G, Harden C, Papakostas G, Labar DR. Left hemispheric dominance of epileptiform discharges. Epilepsia. 1997 Apr; 38(4):503-5. PMID: 9118859.
    Citations: 5     Fields:    Translation:Humans
  204. Albanis TA, Hela D, Papakostas G, Goutner V. Concentration and bioaccumulation of organochlorine pesticide residues in herons and their prey in wetlands of Thermaikos Gulf, Macedonia, Greece. Sci Total Environ. 1996 Apr 05; 182(1-3):11-9. PMID: 8854937.
    Citations: 3     Fields:    Translation:AnimalsPHPublic Health
  205. Daras M, Papakostas G, Tuchman AI. Epilepsy and the ancient world: from the magic beliefs of the Babylonians to the Hippocratic scientific thinking. J Hist Neurosci. 1994 Oct; 3(4):233-6. PMID: 11618824.
    Citations:    Fields:    Translation:Humans